Abstract
GLIPTINS: SAME NEW DRUGS, NON-INFERIORITY OR NO SUPERIORITY
Dick B. S. Brashier*, Dr. Prashant Mishra, Htet Wai Moe, Kedar G. Bandekar, Neha Akhoon
ABSTRACT
Gliptins are a relatively new class of antidiabetic drugs that inhibits dipeptidyl peptidase-4 (DPP-4). They have revolutionized the treatment of type 2 diabetes mellitus as they changed the ways that diabetes and its management has been perceived by clinicians.[1] Gliptins modulate the physiological mechanism which is already in human body and increase the effect of incretin hormones, peptides which are normally released from the endocrine cells in small intestinal mucosa in response to food.
[Full Text Article] [Download Certificate]WJPLS CITATION 
All | Since 2020 | |
Citation | 590 | 424 |
h-index | 12 | 10 |
i10-index | 17 | 14 |
INDEXING
NEWS & UPDATION
BEST ARTICLE AWARDS
World Journal of Pharmaceutical and life sciences is giving Best Article Award in every Issue for Best Article and Issue Certificate of Appreciation to the Authors to promote research activity of scholar.
Best Article of current issue
Download Article : Click here